News and Breakthroughs

Shi-Yuan Cheng, PhD, professor in The Ken and Ruth Davee Department of Neurology in the Division of Neuro-oncology, has been named a fellow of the American Association for the Advancement of Science (AAAS) for his outstanding contributions to molecular and translational cancer research.

Research findings from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting, to be held virtually Dec. 5 – 8, 2020.* With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.

The first randomized phase 3 clinical trial ever to be conducted in patients with advanced cancer of the anal canal is now open and enrolling patients. Anal cancer is a rare disease. The vast majority (90%) of new cases are the squamous cell type, associated with a human papillomavirus (HPV) infection.

A new dataset — the result of a collaborative project between Khan and NUCATS Institute Chief AI Officer Yuan Luo, PhD — has made the process of reviewing thousands of patient histories increasingly possible.

A brief course of immunotherapy resulted in complete and near complete remission in nearly two-thirds of previously untreated patients with classical Hodgkin lymphoma, according to a Northwestern Medicine trial.

The Lurie Cancer Center is partnering with Chill, a Chicago-based meditation organization, to support our patients and staff by providing complimentary access to their app, Chill Anywhere.

The Lurie Cancer Center is pleased to announce the recipients of the 2020 IDP / Sherman Fairchild Foundation Research Innovation Challenge Awards.

The impact of COVID-19 on cancer patients has been a stark reality for many cancer centers around the world. For the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a combination of time and dedication to patient care and research has resulted in the development of robust COVID-19 testing protocols to ensure the safety and health of every patient, physician and staff member.

A new study found that Black men with metastatic prostate cancer were more likely to have tumor mutations than white or Asian men, highlighting the significance genetic drivers have in increasing one's risk for developing aggressive prostate cancer.

Northwestern investigators have developed a novel vaccine that utilizes a specialized group of B-cells to promote anti-tumor immunity against glioblastoma.